---
document_datetime: 2023-09-21 17:11:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/mysimba-epar-all-authorised-presentations_en.pdf
document_name: mysimba-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.729065
conversion_datetime: 2025-12-19 07:08:43.873123
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number       | (Invented) name   | Strength     | Pharmaceutical Form      | Route of Administration   | Immediate Packaging         | Pack size   |
|-----------------|-------------------|--------------|--------------------------|---------------------------|-----------------------------|-------------|
| EU/1/14/988/001 | Mysimba           | 8 mg / 90 mg | Prolonged-release tablet | Oral use                  | blister (PVC/PCTFE/PVC/alu) | 112 tablets |
| EU/1/14/988/002 | Mysimba           | 8 mg / 90 mg | Prolonged-release tablet | Oral use                  | blister (PVC/PCTFE/PVC/alu) | 28 tablets  |